SOMAÍ Pharmaceuticals: A Partnership for Progress
SOMAÍ Pharmaceuticals is teaming up with Georgelle Pharmaceutical Ltd. to offer a wide variety of cannabis-based medicines to patients in Ireland. This strategic partnership is a major step forward, as SOMAÍ seeks to improve access to medical cannabis and meet the increasing needs of patients.
Expanding Internationally
This collaboration marks SOMAÍ's fifth initiative to expand internationally. The company has already established itself in the UK, Australia, Germany, and Poland. Now, as it extends its reach into Ireland, SOMAÍ is making a significant move in its goal to provide innovative cannabis solutions to even more patients worldwide.
A Range of Products for Patients
Under a three-year agreement, SOMAÍ will supply clinics in Ireland that prescribe medical cannabis with a diverse range of cannabinoid products. This exciting lineup will feature different formulations, including THC, CBD, and balanced oral solutions, all designed to address the unique needs of various patients.
Looking Ahead: New Product Innovations
In the future, SOMAÍ plans to introduce terpene-infused oral solutions and inhalation extracts, which will expand the therapeutic options available to patients. These products aim to target specific conditions while enhancing the overall experience of using cannabis-based treatments.
Commitment to Patient Care
Michael Sassano, SOMAÍ's founder and interim CEO, underscores the significance of offering a wide array of treatment options. He remarked, "Providing Irish patients with a full range of products and choices will broaden the demographics needing medicinal cannabis and address the lack of options for self-treatment." This commitment aligns closely with SOMAÍ's core values, focusing on patient well-being and innovation.
Enhancing Access for Irish Patients
This partnership is set to greatly improve access to cannabis-based medicine in Ireland, where treatment options have been scarce. Daniel O'Brien, CSO of Georgelle, praised SOMAÍ's dedication to innovation and positive transformations in the medicinal cannabis field, suggesting that this collaboration could significantly widen the range of available medicines for Irish patients.
Positioning SOMAÍ in the Cannabis Market
This strategic move establishes SOMAÍ Pharmaceuticals as a key player in the Irish medical cannabis market, aligning with its mission to deliver tailored treatment solutions that address patients' unique needs. Through this collaboration, SOMAÍ continues to cement its position as a leader in the realm of cannabis medicines.
Frequently Asked Questions
1. What products will SOMAÍ Pharmaceuticals offer in Ireland?
SOMAÍ will provide Irish clinics with THC, CBD, and balanced oral solutions, along with future terpene-infused products and inhalation extracts.
2. Why is this partnership important for Irish patients?
This partnership enhances access to a broader range of cannabis-based medicines, which is crucial given the limited treatment options currently available in Ireland.
3. Who are the key people involved in this collaboration?
Michael Sassano is the founder and interim CEO of SOMAÍ Pharmaceuticals, and Daniel O'Brien is the CSO of Georgelle Pharmaceutical Ltd.
4. What is the duration of the agreement between SOMAÍ and Georgelle?
The partnership agreement is set for three years, during which the product offerings will expand.
5. How does SOMAÍ plan to address patient needs?
SOMAÍ intends to cater to diverse patient needs by continuously innovating and broadening its product offerings, ensuring effective treatment for various medical conditions.
